Main Article Content
Breast cancer, COVID-19 infection, Outcome
Background: There is no data on the outcome of COVID-19 infection in patients with breast cancer from India. This study was done to assess the outcome of patients with breast cancer who had COVID-19 infection.
Methods: We analyzed patients with breast cancer who were diagnosed with COVID-19 infection from May to September 2020 in the medical oncology department of a tertiary cancer center in India. Symptomatic patients (fever and influenza-like illness symptoms) or asymptomatic patients planned for systemic therapy were tested for COVID-19 by RT-PCR.
Results: A total of 441 breast cancer patients received 1174 systemic therapies from May to September 2020. Among them, 36 patients who had COVID-19 infection were analyzed in detail. The majority (86%) were asymptomatic at presentation. The most common symptoms were fever followed by cough. Patients were either admitted to the hospital (53%) or kept in home quarantine (47%). Patients who received oxygen, non-invasive assisted ventilation (NIV), and mechanical ventilation (MV) were 8%, 3%, and 3% respectively. The median duration of hospitalization and home quarantine was 11 days and 19 days respectively. The recovery of patients with COVID-19 infection was 94%. The median duration to clearing SARS-COV-2 by RT-PCR was 19 days. The total/all-cause mortality was 6% (n=2). The mortality due to COVID-19 infection was 3% (n=1). Subsequently, 89% were restarted on systemic therapy. The median delay in restarting systemic therapy was 23 days.
Conclusion: Systemic therapy can be safely administered during the ongoing COVID19 pandemic. Further, follow-up of patients is warranted to assess the long-term impact of COVID-19 infection.
2. India Coronavirus: 14,074,564 Cases and 173,152 Deaths - Worldometer [Internet]. [cited 2021 Apr 15]. Available from: https://www.worldometers.info/coronavirus/country/india/
3. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783–91.
4. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020 Mar 1;21(3):335–7.
5. Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 Transmission in Patients With Cancer at a Tertiary Care Hospital in Wuhan, China. JAMA Oncol. 2020 Jul 1;6(7):1108–10.
6. Garassino MC, Whisenant JG, Huang L-C, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. The Lancet Oncology. 2020 Jul;21(7):914–22.
7. Vatansev H, Kadiyoran C, Cumhur Cure M, Cure E. COVID-19 infection can cause chemotherapy resistance development in patients with breast cancer and tamoxifen may cause susceptibility to COVID-19 infection. Med Hypotheses. 2020 Oct;143:110091.
8. Vanni G, Materazzo M, Pellicciaro M, Ingallinella S, Rho M, Santori F, et al. Breast Cancer and COVID-19: The Effect of Fear on Patients’ Decision-making Process. In Vivo. 2020 Jun;34(3 Suppl):1651–9.
9. Gathani T, Clayton G, MacInnes E, Horgan K. The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020. British Journal of Cancer. 2021 Feb;124(4):710–2.
10. Gasparri ML, Gentilini OD, Lueftner D, Kuehn T, Kaidar-Person O, Poortmans P. Changes in breast cancer management during the Corona Virus Disease 19 pandemic: An international survey of the European Breast Cancer Research Association of Surgical Trialists (EUBREAST). Breast. 2020 Aug;52:110–5.
11. Brown AH, Shah S, Groves AM, Wan S, Malhotra A. The Challenge of Staging Breast Cancer With PET/CT in the Era of COVID Vaccination. Clin Nucl Med. 2021 Apr 1;
12. Registry Study Describes COVID-19 Mortality and Hospitalization in Patients with Breast Cancer. The Oncologist. 2021;26(S2):S17–8.
13. Vuagnat P, Frelaut M, Ramtohul T, Basse C, Diakite S, Noret A, et al. COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area. Breast Cancer Res [Internet]. 2020 [cited 2021 Apr 15];22. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7254663/
14. Zhang B, Xie R, Hubert SM, Yu Y, Zhang Y, Lei X, et al. Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19. Front Oncol [Internet]. 2020 [cited 2021 Apr 15];10. Available from: https://www.frontiersin.org/articles/10.3389/fonc.2020.570130/full
15. Ovett J, Dhanushkodi M, Radhakrishnan V, Mehra N, Perumal Kalaiyarasi J, Selvarajan G, et al. Coronavirus disease (COVID-19) testing in asymptomatic patients planned for daycare systemic therapy: A tertiary cancer center experience. Indian journal of medical and paediatric oncology. 2020 Nov 12;
16. de Azambuja E, Trapani D, Loibl S, Delaloge S, Senkus E, Criscitiello C, et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer. ESMO Open. 2020;5:e000793.
Article Statistics :Views : 75 | Downloads : 6 : 1